STRUCTURAL-CHANGE IN DOPAMINE D-2 RECEPTOR GENE IN A PATIENT WITH NEUROLEPTIC MALIGNANT SYNDROME

被引:20
作者
RAM, A
CAO, QH
KECK, PE
POPE, HG
OTANI, K
ADDONIZIO, G
MCELROY, SL
KANEKO, S
REDLICHOVA, M
GERSHON, ES
GEJMAN, PV
机构
[1] NIMH,CLIN NEUROGENET BRANCH,MOLEC CLIN INVEST UNIT,BETHESDA,MD 20892
[2] UNIV CINCINNATI,COLL MED,DEPT PSYCHIAT,BIOL PSYCHIAT PROGRAM,CINCINNATI,OH 45267
[3] MCLEAN HOSP,BIOL PSYCHIAT LAB,BELMONT,MA 02178
[4] HARVARD UNIV,SCH MED,BOSTON,MA
[5] CORNELL UNIV,NEW YORK HOSP,CORNELL MED CTR,WESTCHESTER DIV,WHITE PLAINS,NY 10605
[6] HIROSAKI UNIV HOSP,DEPT NEUROPSYCHIAT,HIROSAKI,AOMORI 036,JAPAN
来源
AMERICAN JOURNAL OF MEDICAL GENETICS | 1995年 / 60卷 / 03期
关键词
DOPAMINE D-2 RECEPTOR GENE; NEUROLEPTIC MALIGNANT SYNDROME; ANTIPSYCHOTIC DRUGS; MUTATIONAL ANALYSIS;
D O I
10.1002/ajmg.1320600311
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Dysfunction of the dopaminergic system has been suggested as a pathogenic mechanism in neuroleptic malignant syndrome, Therefore, we examined the complete coding sequences of the dopamine D-2 receptor (DRD2) gene for structural abnormalities in 12 patients with a history of NMS, including two cases of familial NMS, Mutational analysis was performed by denaturing gradient gel electrophoresis (DGGE), a highly sensitive technique for detecting sequence differences, We found in one patient with a history of NMS a nucleotide substitution at codon 310 (CCG-->TCG) of exon 7 of the DRD2 gene which predicts the replacement of proline to serine in the third cytoplasmic loop of the receptor, a part of the receptor that interacts with G-proteins. A larger series of patients with NMS needs to be investigated to establish whether this allele is associated with an increased susceptibility to NMS. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:228 / 230
页数:3
相关论文
共 24 条
[1]  
ADDONIZIO G, 1986, AM J PSYCHIAT, V14, P1587
[2]   DETECTION OF MUTATIONS IN INSULIN-RECEPTOR GENE BY DENATURING GRADIENT GEL-ELECTROPHORESIS [J].
BARBETTI, F ;
GEJMAN, PV ;
TAYLOR, SI ;
RABEN, N ;
CAMA, A ;
BONORA, E ;
PIZZO, P ;
MOGHETTI, P ;
MUGGEO, M ;
ROTH, J .
DIABETES, 1992, 41 (04) :408-415
[3]   NEUROLEPTIC MALIGNANT SYNDROME [J].
CAROFF, SN ;
MANN, SC .
MEDICAL CLINICS OF NORTH AMERICA, 1993, 77 (01) :185-202
[4]   THE DOPAMINE-D2 RECEPTOR - 2 MOLECULAR-FORMS GENERATED BY ALTERNATIVE SPLICING [J].
DALTOSO, R ;
SOMMER, B ;
EWERT, M ;
HERB, A ;
PRITCHETT, DB ;
BACH, A ;
SHIVERS, BD ;
SEEBURG, PH .
EMBO JOURNAL, 1989, 8 (13) :4025-4034
[5]   NEUROLEPTIC MALIGNANT SYNDROME - OBSERVATIONS ON ALTERED CONSCIOUSNESS [J].
DEUSCHL, G ;
OEPEN, G ;
HERMLE, L ;
KINDT, H .
PHARMACOPSYCHIATRY, 1987, 20 (04) :168-170
[6]  
DOHLMAN HG, 1987, BIOCHEMISTRY-US, V2, P2657
[7]   STRUCTURE AND LINKAGE OF THE D2 DOPAMINE RECEPTOR AND NEURAL CELL-ADHESION MOLECULE GENES ON HUMAN CHROMOSOME-11Q23 [J].
EUBANKS, JH ;
DJABALI, M ;
SELLERI, L ;
GRANDY, DK ;
CIVELLI, O ;
MCELLIGOTT, DL ;
EVANS, GA .
GENOMICS, 1992, 14 (04) :1010-1018
[8]  
FERKO AP, 1971, RES COMMUN CHEM PATH, V2, P146
[9]   ANALYSIS OF THE STRUCTURE AND EXPRESSION OF THE HUMAN DOPAMINE-D2A RECEPTOR GENE [J].
GANDELMAN, KY ;
HARMON, S ;
TODD, RD ;
OMALLEY, KL .
JOURNAL OF NEUROCHEMISTRY, 1991, 56 (03) :1024-1029
[10]  
GEJMAN PV, 1994, METHOD ENZYMOL, V237, P308